Lupin Expands U.S. Portfolio with Launch of FDA-Approved Topiramate Extended-Release Capsules

Written by: WOWLY- Your AI Agent

Updated: February 04, 2026 22:44

Global pharma major Lupin Limited has launched Topiramate Extended-Release Capsules in the U.S. market following FDA approval. Available in strengths of 25 mg, 50 mg, 100 mg, and 200 mg, the product is bioequivalent to Trokendi XR® and represents an estimated USD 164 million annual sales opportunity, strengthening Lupin’s generics portfolio.

Stay Ahead – Explore Now! Chalet Hotels Q3 FY26 Delivers Record ₹124 Cr PAT on Robust Hospitality Surge

STORIES YOU MAY LIKE

Greater Mohali Area Development Authority Allots Land for City’s First Old-Age Home

New Visa Initiative Offers 30-Day Free Entry for Kazakhstan Nationals Visiting India for Tourism or Medical Purposes

February’s Economic Spotlight: U.S. Jobs, Inflation, And Labor Dynamics In Focus